92 related articles for article (PubMed ID: 19109947)
1. Proteome-based epitopic peptide scanning along PSA.
Stufano A; Kanduc D
Exp Mol Pathol; 2009 Feb; 86(1):36-40. PubMed ID: 19109947
[TBL] [Abstract][Full Text] [Related]
2. A modified epitope identified for generation and monitoring of PSA-specific T cells in patients on early phases of PSA-based immunotherapeutic protocols.
Lundberg K; Roos AK; Pavlenko M; Leder C; Wehrum D; Guevara-Patiño J; Andersen RS; Pisa P
Vaccine; 2009 Mar; 27(10):1557-65. PubMed ID: 19171173
[TBL] [Abstract][Full Text] [Related]
3. Characterization of prostate-specific antigen binding peptides selected by phage display technology.
Ferrieu-Weisbuch C; Michel S; Collomb-Clerc E; Pothion C; Deléage G; Jolivet-Reynaud C
J Mol Recognit; 2006; 19(1):10-20. PubMed ID: 16312021
[TBL] [Abstract][Full Text] [Related]
4. Computational peptide dissection of Melan-a/MART-1 oncoprotein antigenicity.
Tiwari R; Geliebter J; Lucchese A; Mittelman A; Kanduc D
Peptides; 2004 Nov; 25(11):1865-71. PubMed ID: 15501517
[TBL] [Abstract][Full Text] [Related]
5. Sub-epitopic dissection of HCV E1315-328HRMAWDMMMNWSPT sequence by similarity analysis.
Polimeno L; Mittelman A; Gennero L; Ponzetto A; Lucchese G; Stufano A; Kusalik A; Kanduc D
Amino Acids; 2008 Apr; 34(3):479-84. PubMed ID: 17458624
[TBL] [Abstract][Full Text] [Related]
6. Identification of PSA peptide mimotopes using phage display peptide library.
Shanmugam A; Suriano R; Chaudhuri D; Rajoria S; George A; Mittelman A; Tiwari RK
Peptides; 2011 Jun; 32(6):1097-102. PubMed ID: 21539876
[TBL] [Abstract][Full Text] [Related]
7. Degenerate binding of tyrosinase peptides to MHC II Ad/Ed molecules.
Mittelman A; Lucchese G; Stufano A; Kanduc D
J Exp Ther Oncol; 2007; 6(3):231-9. PubMed ID: 17552363
[TBL] [Abstract][Full Text] [Related]
8. Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis.
Willers J; Lucchese A; Mittelman A; Dummer R; Kanduc D
Exp Dermatol; 2005 Jul; 14(7):543-50. PubMed ID: 15946243
[TBL] [Abstract][Full Text] [Related]
9. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation.
Uhlin M; Okas M; Karlsson H; Gertow J; Henningsohn L; Ringdén O; Kärre K; Levitsky V; Mattsson J
Transplantation; 2009 Feb; 87(4):467-72. PubMed ID: 19307781
[TBL] [Abstract][Full Text] [Related]
10. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
Lubaroff DM; Karan D
Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
[TBL] [Abstract][Full Text] [Related]
11. Strategy for sensitive and specific detection of molecular forms of PSA based on 2DE and kinetic analysis: a step towards diagnosis of prostate cancer.
Kumar V; Hassan MI; Singh AK; Dey S; Singh TP; Yadav S
Clin Chim Acta; 2009 May; 403(1-2):17-22. PubMed ID: 19118539
[TBL] [Abstract][Full Text] [Related]
12. Mapping the human proteome for non-redundant peptide islands.
Capone G; De Marinis A; Simone S; Kusalik A; Kanduc D
Amino Acids; 2008 Jun; 35(1):209-16. PubMed ID: 17701099
[TBL] [Abstract][Full Text] [Related]
13. Widespread and ample peptide overlapping between HCV and Homo sapiens proteomes.
Kusalik A; Bickis M; Lewis C; Li Y; Lucchese G; Marincola FM; Kanduc D
Peptides; 2007 Jun; 28(6):1260-7. PubMed ID: 17485143
[TBL] [Abstract][Full Text] [Related]
14. Non-redundant peptidomes from DAPs: towards "the vaccine"?
Kanduc D; Lucchese A; Mittelman A
Autoimmun Rev; 2007 Apr; 6(5):290-4. PubMed ID: 17412300
[TBL] [Abstract][Full Text] [Related]
15. Sequence uniqueness and sequence variability as modulating factors of human anti-HCV humoral immune response.
Kanduc D; Tessitore L; Lucchese G; Kusalik A; Farber E; Marincola FM
Cancer Immunol Immunother; 2008 Aug; 57(8):1215-23. PubMed ID: 18256830
[TBL] [Abstract][Full Text] [Related]
16. Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid.
Mattsson JM; Valmu L; Laakkonen P; Stenman UH; Koistinen H
Prostate; 2008 Jun; 68(9):945-54. PubMed ID: 18386289
[TBL] [Abstract][Full Text] [Related]
17. Fast and novel purification method to obtain the prostate specific antigen (PSA) from human seminal plasma.
Acevedo B; Perera Y; Torres E; Pentón D; Ayala M; Gavilondo J
Prostate; 2006 Jul; 66(10):1029-36. PubMed ID: 16598740
[TBL] [Abstract][Full Text] [Related]
18. Strategy for surveying the proteome using affinity proteomics and mass spectrometry.
Wingren C; James P; Borrebaeck CA
Proteomics; 2009 Mar; 9(6):1511-7. PubMed ID: 19235165
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic properties of prostate-specific antigen (PSA).
Mattsson JM; Laakkonen P; Stenman UH; Koistinen H
Scand J Clin Lab Invest; 2009; 69(4):447-51. PubMed ID: 19551556
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody.
Ménez R; Michel S; Muller BH; Bossus M; Ducancel F; Jolivet-Reynaud C; Stura EA
J Mol Biol; 2008 Feb; 376(4):1021-33. PubMed ID: 18187150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
